Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | CES1 | P23141 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2287134 | 0.80 | MAOA (0.68) | MEN1KMT2ACES2CES1PTPN1 | |
| SCHEMBL5127523 | 0.80 | MEN1 (0.59) | MEN1KMT2ACES2CES1PTPN1 | |
| SCHEMBL296885 | 0.78 | HDAC6 (0.60) | MEN1KMT2ACES2CES1PTPN1 | |
| SCHEMBL2176500 | 0.78 | TSHR (0.60) | MEN1KMT2ACES2CES1MITF | |
| SCHEMBL11073706 | 0.77 | NPC1 (0.56) | MEN1KMT2ACES2CES1PTPN1 | |
| SCHEMBL6495770 | 0.77 | CES2 (0.61) | MEN1KMT2ACES2CES1PTPN1 | |
| SCHEMBL222973 | 0.76 | MPO (0.64) | MEN1KMT2ACES2CES1PTPN1 | |
| SCHEMBL1883228 | 0.76 | MEN1 (0.55) | MEN1KMT2ACES2CES1PTPN1 | |
| SCHEMBL3104280 | 0.76 | MEN1 (0.55) | MEN1KMT2ACES2CES1PTPN1 | |
| SCHEMBL6973186 | 0.76 | OGG1 (0.61) | MEN1KMT2ACES2CES1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057115-B9 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2012-12-26 | — | — | EP | claimed |
| EP-2057115-B1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2012-10-03 | — | — | EP | claimed |
| US-8183289-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2012-05-22 | — | — | US | claimed |
| US-20100173955-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2010-07-08 | — | — | US | claimed |
| EP-2057115-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | Array Biopharma, Inc. (US) | 2009-05-13 | — | — | EP | claimed |
| WO-2008024746-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| US-8492437-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2057115-B9 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2057115-B1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2012-10-03 | — | — | EP | disclosed |
| US-20120202854-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8183289-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100173955-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2010-07-08 | — | — | US | disclosed |
| EP-2057115-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | Array Biopharma, Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008024746-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173955-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | CD22, HRH2, CD74 | MEN1 4149/4885KMT2A 505/4885CES2 1661/4885 |
| US-20120202854-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | CD22, HRH2, CD74 | MEN1 4149/4885KMT2A 505/4885CES2 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.